Phase Ib Study of CBP-1019 in Combination With FOLFOX +/- Bevacizumab, Pembrolizumab, or Enzalutamide for Metastatic TRPV6-overexpressing Solid Tumors of Epithelial Origin
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Sichuan Baili Pharmaceutical Co., Ltd.
Peking University Cancer Hospital & Institute
ImmunoGenesis
Genentech, Inc.
Jiangsu HengRui Medicine Co., Ltd.
3D Medicines
TCRCure Biopharma Ltd.
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Children's National Research Institute
M.D. Anderson Cancer Center
Mabwell (Shanghai) Bioscience Co., Ltd.
Novartis
Biohaven Pharmaceuticals, Inc.
Sichuan Huiyu Pharmaceutical Co., Ltd
Georgetown University
Salubris Biotherapeutics Inc
Peking University Cancer Hospital & Institute
Emory University
St. Jude Children's Research Hospital
Memorial Sloan Kettering Cancer Center
Advenchen Laboratories, LLC
Innovent Biologics Technology Limited (Shanghai R&D Center)
Binhui Biopharmaceutical Co., Ltd.
Axcynsis Therapeutics Pte Ltd
Suzhou Biomissile Pharmaceuticals Co., Ltd.
Memorial Sloan Kettering Cancer Center
Sanofi